Current treatments of Chronic ITP include Eltrombopag, Romiplostim, and Avatrombopag (DOPTELET). However, Doptelet provides unique benefits in that it can be orally taken as a pill once daily without restrictions on diet or requiring a provider unlike the other available treatments. This study aims to characterize the switch from other available treatments to doptelet and measure the safety, efficacy, and patient reported satisfaction with avatrombopag for 90 days.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Raj Kasthuri
Medicine-Hematology
Clinical or Medical
Interventional
Blood Conditions
Chronic Conditions
Genetics and Genetic Disorders
Immune System/Infections
Rare Diseases
Wellness and Lifestyle
21-1849
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
